Mesalamine therapy in Reiter's syndrome.
A patient with chronic Reiter's syndrome (RS) refractory to nonsteroidal antiinflammatory therapy was prescribed mesalamine (Pentasa) therapy for a 4-month trial. Nine months after discontinuing therapy, mesalamine was reintroduced. A pre and posttreatment ileocolonoscopy with distal ileum biopsy was performed. Our patient responded well to mesalamine therapy as measured by improvement in joint count, morning stiffness, and fatigue. Symptoms returned after cessation of therapy. His RS once again went into remission after reintroduction of mesalamine. The pretreatment biopsy revealed inflammatory lesions usually described in the spondyloarthropathies. These lesions improved with resumption of mesalamine therapy.
Thomson
G T
GT
Rheumatic Disease Unit, University of Toronto, Canada.
McKibbon
C
C
Inman
R D
RD
D000328:Adult; D000636:Aminosalicylic Acids / Q000627:therapeutic use*; D016918:Arthritis, Reactive / Q000150:complications / Q000188:drug therapy*; D003092:Colitis / Q000188:drug therapy / Q000209:etiology; D005759:Gastroenteritis / Q000150:complications; D006801:Humans; D007079:Ileitis / Q000188:drug therapy / Q000209:etiology; D008297:Male; D019804:Mesalamine; D012074:Remission Induction
D000636:Aminosalicylic Acids; D019804:Mesalamine